Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sysmex Corporation
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.
Three years after the US FDA released a guidance to use real-world evidence in premarket applications, the stakeholder group MDIC has unveiled a framework for how IVD RWE can be captured and used by sponsors for premarket applications.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Diagnostic Equipment & Supplies
- Other Names / Subsidiaries
- D’PULA Medical Solutions Corporation
- Oxford Gene Technology
- RIKEN GENESIS
- Sysmex Egypt LLC
- Sysmex Middle East FZ-LLC
- TOA Medical Electronics Co., Ltd.
- Medicaroid, Inc
- Medicaroid Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.